{
    "name": "teclistamab",
    "comment": "Rx",
    "other_names": [
        "Tecvayli"
    ],
    "classes": [
        "Anti-BCMA Antibodies"
    ],
    "source": "https://reference.medscape.com/drug/tecvayli-teclistamab-4000281",
    "pregnancy": {
        "common": [
            "Based on mechanism of action, fetal harm may occur when administered to pregnant females",
            "There are no available data on use in pregnant females",
            "No animal reproductive or developmental toxicity studies conducted ",
            "Teclistamab causes T-cell activation and cytokine release; immune activation may compromise pregnancy maintenance",
            "Human immunoglobulin G (IgG) is known to cross the placenta; therefore, teclistamab may potentially transmit from mother to developing fetus",
            "Advise females of potential risk to fetus",
            "Verify pregnancy status of females of reproductive potential before initiating "
        ],
        "specific": [
            {
                "type": "Contraception",
                "description": [
                    "Females of reproductive potential: Use effective contraception during treatment and for 5 months after final dose"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There are no data on the presence of teclistamab in human milk, effect on breastfed children, or effects on milk production",
            "Maternal IgG is known to be present in human milk",
            "Advise patients not to breastfeed during treatment and for 5 months after final dose"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [
                "BLACK BOX WARNINGS"
            ],
            "specific": [
                {
                    "type": "Cytokine release syndrome",
                    "description": [
                        "Cytokine release syndrome (CRS), including life-threatening or fatal reactions, can occur",
                        "Initiate treatment step-up dosing schedule to reduce risk of CRS",
                        "Withhold until CRS resolves or permanently discontinue based on severity"
                    ]
                },
                {
                    "type": "Neurologic toxicity",
                    "description": [
                        "Neurologic toxicity, including immune effector cell-associated neurotoxicity syndrome (ICANS), and serious and life-threatening reactions, can occur ",
                        "Monitor for signs or symptoms of neurologic toxicity, including ICANS, during treatment",
                        "Withhold until neurologic toxicity resolves or permanently discontinue based on severity ",
                        "Owing to these risks, available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called Tecvayli REMS "
                    ]
                }
            ]
        },
        "contraindicators": {
            "common": [],
            "specific": []
        },
        "cautions": {
            "common": [
                "Hepatotoxicity, including fatalities reported; monitor liver enzymes and bilirubin at baseline and during treatment as clinically indicated",
                "Neutropenia and febrile neutropenia reported; monitor complete blood cell counts at baseline and periodically during treatment and provide supportive care per local institutional guidelines; monitor with neutropenia for signs of infection ",
                "Based on its mechanism of action, fetal harm may occur when administered to pregnant females ",
                " "
            ],
            "specific": [
                {
                    "type": "Hypersensitivity",
                    "description": [
                        "May cause both systemic administration-related reactions and local injection-site reactions; withhold or consider permanent discontinuation of therapy based on severity",
                        "May cause systemic-administration reactions, which included Grade 1 recurrent pyrexia and Grade 1 swollen tongue ",
                        "Injection-site reactions occurred reported "
                    ]
                },
                {
                    "type": "CRS",
                    "description": [
                        "May cause CRS, including life-threatening or fatal reactions ",
                        "Median time to onset of CRS was 2 days after most recent dose with a median duration of 2 days",
                        "Clinical signs and symptoms of CRS included fever, hypoxia, chills, hypotension, sinus tachycardia, headache, and elevated AST/ALT",
                        "Initiate therapy according to step-up dosing schedule to reduce risk of CRS",
                        "Premedicate to reduce risk of CRS and monitor following administration ",
                        "At first sign of CRS, immediately evaluate for hospitalization",
                        "Administer supportive care based on severity and consider further management per current practice guidelines"
                    ]
                },
                {
                    "type": "Neurologic toxicity",
                    "description": [
                        "Serious or life-threatening neurologic toxicity, including ICANS may occur",
                        "Median time to onset of ICANS was 4 days after most recent dose with a median duration of 3 days",
                        "Reported clinical manifestations were confusional state and dysgraphia",
                        "Onset of ICANS can be concurrent with CRS, following resolution of CRS, or in the absence of CRS",
                        "Monitor for signs and symptoms of neurologic toxicity during treatment",
                        "At first sign of neurologic toxicity, including ICANS, immediately evaluate and provide supportive therapy based on severity",
                        "Due to potential for neurologic toxicity, treated patients are at risk of depressed level of consciousness ",
                        "Advise patients to refrain from driving or operating heavy or potentially dangerous machinery during and for 48 hr after completion of step-up dosing schedule and in the event of new onset of any neurologic toxicity symptoms until neurologic toxicity resolves"
                    ]
                },
                {
                    "type": "Infections",
                    "description": [
                        "Severe, life-threatening, or fatal infections reported",
                        "Monitor for signs and symptoms of infection before and during treatment and treat appropriately",
                        "Administer prophylactic antimicrobials according to guidelines",
                        "Monitor immunoglobulin levels during treatment and treat according to guidelines, including infection precautions and antibiotic or antiviral prophylaxis"
                    ]
                },
                {
                    "type": "REMS",
                    "description": [
                        "Available only through a restricted program under a REMS called Tecvayli REMS ",
                        "Notable requirements of REMS include following:",
                        "Prescribers must be certified with program by enrolling and completing training",
                        "Prescribers must counsel treated patients about risk of CRS and neurologic toxicity, including ICANS, and provide patients with Patient Wallet Card",
                        "Pharmacies and healthcare settings that dispense must be certified with REMS program and must verify prescribers are certified through REMS program",
                        "Wholesalers and distributors must only distribute to certified pharmacies or healthcare settings",
                        "Further information about Tecvayli REMS program is available at www.TECVAYLIREMS.com or by telephone at 1-855-810-8064 "
                    ]
                },
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "May cause release of cytokines that may suppress activity of CYP enzymes, resulting in increased exposure of CYP substrates",
                        "Highest risk of drug-drug interaction is expected to occur from initiating step-up dosing schedule up to 7 days after first treatment dose and during and after CRS",
                        "Monitor for toxicity or concentrations of CYP substrates where minimal concentration changes may lead to serious adverse reactions ",
                        "Adjust dose of concomitant CYP substrate drug as needed "
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "alfentanil",
            "description": {
                "common": "teclistamab will increase the level or effect of alfentanil by  altering metabolism. Use Caution/Monitor. Teclistamab causes release of cytokines that may suppress activity of CYP450 enzymes, resulting in increased exposure of CYP substrates. Monitor for increased concentrations or toxicities of sensitive CYP substrates. Adjust dose of CYP substrate drug as needed. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carbamazepine",
            "description": {
                "common": "teclistamab will increase the level or effect of carbamazepine by  altering metabolism. Use Caution/Monitor. Teclistamab causes release of cytokines that may suppress activity of CYP450 enzymes, resulting in increased exposure of CYP substrates. Monitor for increased concentrations or toxicities of sensitive CYP substrates. Adjust dose of CYP substrate drug as needed. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clonidine",
            "description": {
                "common": "teclistamab will increase the level or effect of clonidine by  altering metabolism. Use Caution/Monitor. Teclistamab causes release of cytokines that may suppress activity of CYP450 enzymes, resulting in increased exposure of CYP substrates. Monitor for increased concentrations or toxicities of sensitive CYP substrates. Adjust dose of CYP substrate drug as needed. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "colchicine",
            "description": {
                "common": "teclistamab will increase the level or effect of colchicine by  altering metabolism. Use Caution/Monitor. Teclistamab causes release of cytokines that may suppress activity of CYP450 enzymes, resulting in increased exposure of CYP substrates. Monitor for increased concentrations or toxicities of sensitive CYP substrates. Adjust dose of CYP substrate drug as needed. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cyclosporine",
            "description": {
                "common": "teclistamab will increase the level or effect of cyclosporine by  altering metabolism. Use Caution/Monitor. Teclistamab causes release of cytokines that may suppress activity of CYP450 enzymes, resulting in increased exposure of CYP substrates. Monitor for increased concentrations or toxicities of sensitive CYP substrates. Adjust dose of CYP substrate drug as needed. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dihydroergotamine",
            "description": {
                "common": "teclistamab will increase the level or effect of dihydroergotamine by  altering metabolism. Use Caution/Monitor. Teclistamab causes release of cytokines that may suppress activity of CYP450 enzymes, resulting in increased exposure of CYP substrates. Monitor for increased concentrations or toxicities of sensitive CYP substrates. Adjust dose of CYP substrate drug as needed. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "disopyramide",
            "description": {
                "common": "teclistamab will increase the level or effect of disopyramide by  altering metabolism. Use Caution/Monitor. Teclistamab causes release of cytokines that may suppress activity of CYP450 enzymes, resulting in increased exposure of CYP substrates. Monitor for increased concentrations or toxicities of sensitive CYP substrates. Adjust dose of CYP substrate drug as needed. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "divalproex sodium",
            "description": {
                "common": "teclistamab will increase the level or effect of divalproex sodium by  altering metabolism. Use Caution/Monitor. Teclistamab causes release of cytokines that may suppress activity of CYP450 enzymes, resulting in increased exposure of CYP substrates. Monitor for increased concentrations or toxicities of sensitive CYP substrates. Adjust dose of CYP substrate drug as needed. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ergotamine",
            "description": {
                "common": "teclistamab will increase the level or effect of ergotamine by  altering metabolism. Use Caution/Monitor. Teclistamab causes release of cytokines that may suppress activity of CYP450 enzymes, resulting in increased exposure of CYP substrates. Monitor for increased concentrations or toxicities of sensitive CYP substrates. Adjust dose of CYP substrate drug as needed. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ethosuximide",
            "description": {
                "common": "teclistamab will increase the level or effect of ethosuximide by  altering metabolism. Use Caution/Monitor. Teclistamab causes release of cytokines that may suppress activity of CYP450 enzymes, resulting in increased exposure of CYP substrates. Monitor for increased concentrations or toxicities of sensitive CYP substrates. Adjust dose of CYP substrate drug as needed. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "everolimus",
            "description": {
                "common": "teclistamab will increase the level or effect of everolimus by  altering metabolism. Use Caution/Monitor. Teclistamab causes release of cytokines that may suppress activity of CYP450 enzymes, resulting in increased exposure of CYP substrates. Monitor for increased concentrations or toxicities of sensitive CYP substrates. Adjust dose of CYP substrate drug as needed. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fentanyl",
            "description": {
                "common": "teclistamab will increase the level or effect of fentanyl by  altering metabolism. Use Caution/Monitor. Teclistamab causes release of cytokines that may suppress activity of CYP450 enzymes, resulting in increased exposure of CYP substrates. Monitor for increased concentrations or toxicities of sensitive CYP substrates. Adjust dose of CYP substrate drug as needed. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fosphenytoin",
            "description": {
                "common": "teclistamab will increase the level or effect of fosphenytoin by  altering metabolism. Use Caution/Monitor. Teclistamab causes release of cytokines that may suppress activity of CYP450 enzymes, resulting in increased exposure of CYP substrates. Monitor for increased concentrations or toxicities of sensitive CYP substrates. Adjust dose of CYP substrate drug as needed. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "midazolam",
            "description": {
                "common": "teclistamab will increase the level or effect of midazolam by  altering metabolism. Use Caution/Monitor. Teclistamab causes release of cytokines that may suppress activity of CYP450 enzymes, resulting in increased exposure of CYP substrates. Monitor for increased concentrations or toxicities of sensitive CYP substrates. Adjust dose of CYP substrate drug as needed. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pacritinib",
            "description": {
                "common": "teclistamab will increase the level or effect of pacritinib by  altering metabolism. Use Caution/Monitor. Teclistamab causes release of cytokines that may suppress activity of CYP450 enzymes, resulting in increased exposure of CYP substrates. Monitor for increased concentrations or toxicities of sensitive CYP substrates. Adjust dose of CYP substrate drug as needed. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phenobarbital",
            "description": {
                "common": "teclistamab will increase the level or effect of phenobarbital by  altering metabolism. Use Caution/Monitor. Teclistamab causes release of cytokines that may suppress activity of CYP450 enzymes, resulting in increased exposure of CYP substrates. Monitor for increased concentrations or toxicities of sensitive CYP substrates. Adjust dose of CYP substrate drug as needed. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phenytoin",
            "description": {
                "common": "teclistamab will increase the level or effect of phenytoin by  altering metabolism. Use Caution/Monitor. Teclistamab causes release of cytokines that may suppress activity of CYP450 enzymes, resulting in increased exposure of CYP substrates. Monitor for increased concentrations or toxicities of sensitive CYP substrates. Adjust dose of CYP substrate drug as needed. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pimozide",
            "description": {
                "common": "teclistamab will increase the level or effect of pimozide by  altering metabolism. Use Caution/Monitor. Teclistamab causes release of cytokines that may suppress activity of CYP450 enzymes, resulting in increased exposure of CYP substrates. Monitor for increased concentrations or toxicities of sensitive CYP substrates. Adjust dose of CYP substrate drug as needed. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "primidone",
            "description": {
                "common": "teclistamab will increase the level or effect of primidone by  altering metabolism. Use Caution/Monitor. Teclistamab causes release of cytokines that may suppress activity of CYP450 enzymes, resulting in increased exposure of CYP substrates. Monitor for increased concentrations or toxicities of sensitive CYP substrates. Adjust dose of CYP substrate drug as needed. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "quinidine",
            "description": {
                "common": "teclistamab will increase the level or effect of quinidine by  altering metabolism. Use Caution/Monitor. Teclistamab causes release of cytokines that may suppress activity of CYP450 enzymes, resulting in increased exposure of CYP substrates. Monitor for increased concentrations or toxicities of sensitive CYP substrates. Adjust dose of CYP substrate drug as needed. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "quinine",
            "description": {
                "common": "teclistamab will increase the level or effect of quinine by  altering metabolism. Use Caution/Monitor. Teclistamab causes release of cytokines that may suppress activity of CYP450 enzymes, resulting in increased exposure of CYP substrates. Monitor for increased concentrations or toxicities of sensitive CYP substrates. Adjust dose of CYP substrate drug as needed. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "repaglinide",
            "description": {
                "common": "teclistamab will increase the level or effect of repaglinide by  altering metabolism. Use Caution/Monitor. Teclistamab causes release of cytokines that may suppress activity of CYP450 enzymes, resulting in increased exposure of CYP substrates. Monitor for increased concentrations or toxicities of sensitive CYP substrates. Adjust dose of CYP substrate drug as needed. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sirolimus",
            "description": {
                "common": "teclistamab will increase the level or effect of sirolimus by  altering metabolism. Use Caution/Monitor. Teclistamab causes release of cytokines that may suppress activity of CYP450 enzymes, resulting in increased exposure of CYP substrates. Monitor for increased concentrations or toxicities of sensitive CYP substrates. Adjust dose of CYP substrate drug as needed. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tacrolimus",
            "description": {
                "common": "teclistamab will increase the level or effect of tacrolimus by  altering metabolism. Use Caution/Monitor. Teclistamab causes release of cytokines that may suppress activity of CYP450 enzymes, resulting in increased exposure of CYP substrates. Monitor for increased concentrations or toxicities of sensitive CYP substrates. Adjust dose of CYP substrate drug as needed. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "theophylline",
            "description": {
                "common": "teclistamab will increase the level or effect of theophylline by  altering metabolism. Use Caution/Monitor. Teclistamab causes release of cytokines that may suppress activity of CYP450 enzymes, resulting in increased exposure of CYP substrates. Monitor for increased concentrations or toxicities of sensitive CYP substrates. Adjust dose of CYP substrate drug as needed. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "thioridazine",
            "description": {
                "common": "teclistamab will increase the level or effect of thioridazine by  altering metabolism. Use Caution/Monitor. Teclistamab causes release of cytokines that may suppress activity of CYP450 enzymes, resulting in increased exposure of CYP substrates. Monitor for increased concentrations or toxicities of sensitive CYP substrates. Adjust dose of CYP substrate drug as needed. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "triazolam",
            "description": {
                "common": "teclistamab will increase the level or effect of triazolam by  altering metabolism. Use Caution/Monitor. Teclistamab causes release of cytokines that may suppress activity of CYP450 enzymes, resulting in increased exposure of CYP substrates. Monitor for increased concentrations or toxicities of sensitive CYP substrates. Adjust dose of CYP substrate drug as needed. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "valproic acid",
            "description": {
                "common": "teclistamab will increase the level or effect of valproic acid by  altering metabolism. Use Caution/Monitor. Teclistamab causes release of cytokines that may suppress activity of CYP450 enzymes, resulting in increased exposure of CYP substrates. Monitor for increased concentrations or toxicities of sensitive CYP substrates. Adjust dose of CYP substrate drug as needed. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "warfarin",
            "description": {
                "common": "teclistamab will increase the level or effect of warfarin by  altering metabolism. Use Caution/Monitor. Teclistamab causes release of cytokines that may suppress activity of CYP450 enzymes, resulting in increased exposure of CYP substrates. Monitor for increased concentrations or toxicities of sensitive CYP substrates. Adjust dose of CYP substrate drug as needed. "
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Lymphocyte count decreased",
            "percent": "92"
        },
        {
            "name": "White blood cell decreased",
            "percent": "86"
        },
        {
            "name": "Neutrophil count decreased",
            "percent": "84"
        },
        {
            "name": "Pyrexia",
            "percent": "76"
        },
        {
            "name": "Cytokine release syndrome",
            "percent": "72"
        },
        {
            "name": "Platelet count decreased",
            "percent": "71"
        },
        {
            "name": "Albumin decreased",
            "percent": "68"
        },
        {
            "name": "Hemoglobin decreased",
            "percent": "67"
        },
        {
            "name": "Musculoskeletal pain",
            "percent": "44"
        },
        {
            "name": "White blood cell decreased",
            "percent": "41"
        },
        {
            "name": "Alkaline phosphatase increased",
            "percent": "42"
        },
        {
            "name": "Phosphorus decreased",
            "percent": "38"
        },
        {
            "name": "Injection site reaction",
            "percent": "37"
        },
        {
            "name": "Gamma",
            "percent": "37"
        },
        {
            "name": "glutamyl transferase increased",
            "percent": "35"
        },
        {
            "name": "Sodium decreased",
            "percent": "33"
        },
        {
            "name": "Fatigue",
            "percent": "31"
        },
        {
            "name": "Calcium",
            "percent": "30"
        },
        {
            "name": "corrected",
            "percent": "26"
        },
        {
            "name": "decreased",
            "percent": "25"
        },
        {
            "name": "Creatinine increased",
            "percent": "25"
        },
        {
            "name": "Upper respiratory tract infection",
            "percent": "24"
        },
        {
            "name": "Headache",
            "percent": "21"
        },
        {
            "name": "Nausea",
            "percent": "18"
        },
        {
            "name": "Pneumonia",
            "percent": "18"
        },
        {
            "name": "Diarrhea",
            "percent": "18"
        },
        {
            "name": "Constipation",
            "percent": "16"
        },
        {
            "name": "Hypoxia",
            "percent": "16"
        },
        {
            "name": "Hypotension",
            "percent": "16"
        },
        {
            "name": "Chills",
            "percent": "16"
        },
        {
            "name": "Bone pain",
            "percent": "15"
        },
        {
            "name": "Motor dysfunction",
            "percent": "15"
        },
        {
            "name": "Cardiac arrhythmia",
            "percent": "15"
        },
        {
            "name": "Sensory neuropathy",
            "percent": "13"
        },
        {
            "name": "Cough",
            "percent": "13"
        },
        {
            "name": "Pain",
            "percent": "12"
        },
        {
            "name": "Edema",
            "percent": "12"
        },
        {
            "name": "Encephalopathy",
            "percent": "12"
        },
        {
            "name": "Hemorrhage",
            "percent": "11"
        },
        {
            "name": "Hypertension",
            "percent": "11"
        },
        {
            "name": "Vomiting",
            "percent": "11"
        },
        {
            "name": "Hypogammaglobulinemia",
            "percent": "11"
        },
        {
            "name": "Urinary tract infection",
            "percent": "84"
        },
        {
            "name": "Decreased appetite",
            "percent": "56"
        },
        {
            "name": "Acute kidney injury",
            "percent": "33"
        },
        {
            "name": "Lymphocyte count decreased",
            "percent": "22"
        },
        {
            "name": "Neutrophil count decreased",
            "percent": "15"
        },
        {
            "name": "Hemoglobin decreased",
            "percent": "10"
        },
        {
            "name": "Platelet count decreased",
            "percent": "8"
        },
        {
            "name": "Pneumonia",
            "percent": "6"
        },
        {
            "name": "Sodium decreased",
            "percent": "5"
        },
        {
            "name": "Gamma",
            "percent": "4.8"
        },
        {
            "name": "glutamyl transferase increased",
            "percent": "4.2"
        },
        {
            "name": "Albumin decreased",
            "percent": "3.6"
        },
        {
            "name": "Urinary tract infection",
            "percent": "3"
        },
        {
            "name": "Hypertension",
            "percent": "3"
        },
        {
            "name": "Musculoskeletal pain",
            "percent": "3"
        },
        {
            "name": "Acute kidney injury",
            "percent": "2.4"
        },
        {
            "name": "Pyrexia",
            "percent": "2.4"
        },
        {
            "name": "Bone pain",
            "percent": "2.4"
        },
        {
            "name": "Creatinine increased",
            "percent": "2.4"
        },
        {
            "name": "Fatigue",
            "percent": "1.8"
        },
        {
            "name": "Upper respiratory tract infection",
            "percent": "1.8"
        },
        {
            "name": "Diarrhea",
            "percent": "1.8"
        },
        {
            "name": "Alkaline phosphatase increased",
            "percent": "1.8"
        },
        {
            "name": "Pain",
            "percent": "1.2"
        },
        {
            "name": "Hemorrhage",
            "percent": "1.2"
        },
        {
            "name": "Hypoxia",
            "percent": "1.2"
        },
        {
            "name": "Cardiac arrhythmia",
            "percent": "1.2"
        },
        {
            "name": "Hypogammaglobulinemia",
            "percent": "1.2"
        },
        {
            "name": "Sensory neuropathy",
            "percent": "0.6"
        },
        {
            "name": "Hypotension",
            "percent": "0.6"
        },
        {
            "name": "AST increased",
            "percent": "0.6"
        },
        {
            "name": "Calcium",
            "percent": "0.6"
        },
        {
            "name": "corrected",
            "percent": "0.6"
        },
        {
            "name": "decreased",
            "percent": "0.6"
        },
        {
            "name": "Injection site reaction",
            "percent": null
        },
        {
            "name": "Cytokine release syndrome",
            "percent": null
        },
        {
            "name": "Nausea",
            "percent": null
        },
        {
            "name": "Decreased appetite",
            "percent": null
        },
        {
            "name": "Vomiting",
            "percent": null
        },
        {
            "name": "Headache",
            "percent": null
        }
    ]
}